deltatrials
Completed PHASE3 INTERVENTIONAL 2-arm NCT00033917

Indomethacin Germinal Matrix Hemorrhage/Intraventricular Hemorrhage (GMH/IVH) Prevention Trial

Randomized Indomethacin Germinal Matrix Hemorrhage/Intraventricular Hemorrhage (GMH/IVH) Prevention Trial

Sponsor: Yale University

Conditions Bleeding in the Brain Intraventricular Hemorrhage (IVH) Prematurity Very Low Birth Weight Infants
Interventions indomethacin placebo
Updated 7 times since 2017 Last updated: Feb 20, 2013 Started: Sep 30, 1989 Primary completion: Mar 31, 2012 Completion: Mar 31, 2012
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT00033917, this PHASE3 trial focuses on Bleeding in the Brain and Intraventricular Hemorrhage (IVH) and remains completed. Sponsored by Yale University, it has been updated 7 times since 1989, reflecting limited change activity. This study contributes longitudinal data to the cardiovascular research landscape.

Status Flow

~Jan 2017 – ~Jun 2018 · 17 months · monthly snapshotCompleted~Jun 2018 – ~Jan 2021 · 31 months · monthly snapshotCompleted~Jan 2021 – ~Dec 2022 · 23 months · monthly snapshotCompleted~Dec 2022 – ~Jan 2023 · 31 days · monthly snapshotCompleted~Jan 2023 – ~Jul 2024 · 18 months · monthly snapshotCompleted~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshotCompleted~Sep 2024 – present · 22 months · monthly snapshotCompleted

Change History

7 versions recorded

  1. Sep 2024 — Present [monthly]

    Completed PHASE3

  2. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE3

  3. Jan 2023 — Jul 2024 [monthly]

    Completed PHASE3

  4. Dec 2022 — Jan 2023 [monthly]

    Completed PHASE3

  5. Jan 2021 — Dec 2022 [monthly]

    Completed PHASE3

▶ Show 2 earlier versions

  1. Jun 2018 — Jan 2021 [monthly]

    Completed PHASE3

  2. Jan 2017 — Jun 2018 [monthly]

    Completed PHASE3

    First recorded

Sep 1989

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Yale University
Data source: Yale University

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations